TELA BIO INC. - COMMON STOCK

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

26 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

15 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

TELA Bio to Participate in the Jefferies Global Healthcare Conference

25 May 2023 07:00:00 By Nasdaq GlobeNewswire

TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab

19 May 2023 07:00:00 By Nasdaq GlobeNewswire

TELA Bio Reports First Quarter 2023 Financial Results

11 May 2023 16:02:00 By Nasdaq GlobeNewswire

TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference

09 May 2023 07:00:01 By Nasdaq GlobeNewswire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 May 2023 16:30:00 By Nasdaq GlobeNewswire

TELA Bio to Participate in the JMP Securities Life Sciences Conference

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

TELA Bio to Announce First Quarter 2023 Financial Results

27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

TELA Bio Announces Pricing of Public Offering of Common Stock

18 Apr 2023 23:00:00 By Nasdaq GlobeNewswire

TELA Bio Announces Proposed Public Offering of Common Stock

18 Apr 2023 16:01:00 By Nasdaq GlobeNewswire

TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

29 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

23 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results

21 Mar 2023 16:02:00 By Nasdaq GlobeNewswire

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

16 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24 Feb 2023 16:02:00 By Nasdaq GlobeNewswire

TELA Bio Announces U.S. Commercial Launch of Two New OviTex® LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques

21 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

TELA Bio Awarded Biosynthetic Mesh Products Agreement with a National Group Purchasing Organization

14 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

TELA Bio Announces U.S. Commercial Launch of NIVIS™ Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire